Index of artpub/2023/296646/

Papp, K.A
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis : Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
2023
https://ddd.uab.cat/record/296646